Combined non-responder group, N=27 (A) Combined non-responder group, N=27 (A) Omalizumab responder,
N=92 (B) Omalizumab responder,
N=92 (B) Mepolizumab responder,
N=43 (C) Mepolizumab responder,
N=43 (C) Severe asthma, non-biologic group, N=178 (D) Severe asthma, non-biologic group, N=178 (D) P values P values P values
Mean (SD) / Median (IQR) Missing Mean (SD) / Median (IQR) Missing Mean (SD) / Median (IQR) Missing Mean (SD) / Median (IQR) Missing A vs B A vs C A vs D
Annualised rate of exacerbations, median (IQR) 4 (5) † 2 5 (2) † 1 4 (5) † 1 5 (3) ‡ 32 0.526 0.864 0.978
Annualised rate of AHE, median (IQR) 1 (3) † 1 0 (2) † 8 0 (1) † 2 0 (1) ‡ 1 0.095 0.002 0.028
Maximum Eos count in the past year, median (IQR) - cells/µL 400 (400) † 2 200 (400) † 7 500 (500) † 0 200 (300) ‡ 49 0.005 0.178 <0.001
ACQ6, median (IQR) 3.67 (1.26) § 6 3 (1.83) § 20 2.33 (2.27) § 2 3 (1.8) ‡ 11 0.036 <0.001 0.017
FENO, median (IQR) - ppb 22 (59.6) § 4 29.5 (37) § 24 37 (46.5) § 2 16.85 (24.65) ‡ 50 0.514 0.129 0.383
Clinic FEV1 %, mean (SD) 61.64 (21.75) § 1 68.13 (20.49) § 6 67% (20.1) § 1 76.78 (23.37) ‡ 57 0.483 0.909 0.003
BMI, median (IQR) -kgm-2 30.6 (15.9) 0 30.36 (5.99) 0 29.1 (11.5) 0 30.8 (10.8) 3 0.194 0.160 0.469
Age at asthma diagnosis, median (IQR) - y 12 (31) 0 11 (25.5) 3 33.5 (40.5) 1 20 (35) 9 0.627 0.032 0.355
Age, median (IQR) - y 54 (28) 0 53 (20.5) 0 61 (19) 0 54.5 (25) 0 0.871 0.110 0.997
Percentage (N) Missing Percentage (N) Missing Percentage (N) Missing Percentage (N) Missing A vs B A vs C A vs D
Multiple (>1) AHE, Yes 48% (12) † 2 27.4% (23) † 8 9.8% (4) † 2 24.3% (43) ‡ 5 0.053 0.001 <0.001
On maintenance OCS, Yes 66.7% (18) § 0 46.7% (43) § 0 69.8% (30) § 0 30.6% (53) ‡ 1 0.069 0.797 0.013
Adult-onset asthma, Yes 38.5% (10) 0 39.3% (35) 1 61.9% (26) 1 52.7% (89) 9 1.000 0.060 0.178
Sex, Male 33.3% (9) 0 35.9% (33) 0 58.1% (25) 0 29.8% (53) 0 1.000 0.043 0.822
Ethnicity, White 92.6% (25) 0 89.1% (82) 0 90.7% (39) 0 94.9% (169) 0 0.732 1.000 0.642
Rhinitis, Ever 80.8% (21) 1 73.0% (54) 22 68.3% (28) 2 60.1% (95) 10 0.430 0.262 0.043
GORD, Ever 73.1% (19) 1 64.1% (59) 0 61.9% (26) 1 65.3% (111) 8 0.485 0.344 0.434
Smoking, Ever 51.9% (14) 0 43.5% (40) 0 53.5% (23) 0 47.5% (84) 1 0.442 0.894 0.670
Atopy (SPT /sIgE positive) 74.0% (20) 0 100% (92) 0 51.2% (22) 0 52.8% (94) 0 <0.001 0.057 0.038
Obesity (BMI≥30kgm-2), Ever 55.6% (15) 0 50.0% (46) 0 41.9% (18) 0 52.6% (92) 3 0.612 0.190 0.772
ICU admission for asthma, Ever 33.3% (9) 0 26.4% (24) 1 37.2% (16) 0 32.6% (58) 0 0.479 0.802 1.000
Intubated for Asthma, Ever 18.5% (5) 0 14.3% (13) 1 9.3% (4) 0 17.4% (31) 0 0.591 0.292 1.000
Dysfunctional breathing, Ever 59.3% (16) 0 48.8% (42) 6 31.7% (13) 2 55.1% (92) 11 0.345 0.025 0.686
ILO, Ever 25.9% (7) 0 17.5% (14) 12 7.7% (3) 4 13.2% (21) 19 0.340 0.077 0.140
Depression, Ever 48% (12) 2 30.4% (24) 13 19.1% (8) 1 42.8% (68) 19 0.107 0.012 0.624
Anxiety, Ever 50% (13) 1 26.6% (21) 13 20.0% (8) 3 38.0% (60) 19 0.027 0.011 0.245
Bronchiectasis, Ever 18.5% (5) 0 14.4% (13) 2 18.6% (8) 0 14.2% (25) 2 0.560 1.000 0.563
Salicylate sensitivity, Ever 18.5% (5) 0 33.3% (30) 2 18.6% (8) 0 27.8% (49) 2 0.140 1.000 0.307
ABPA, Ever 14.8% (4) 0 12.2% (11) 2 14.0% (6) 0 5.2% (9) 4 0.746 1.000 0.079
Sulphite sensitivity, Ever 7.4% (2) 0 7.8% (7) 2 11.6% (5) 0 7.4% (13) 3 1.000 0.699 1.000
COPD, Ever 7.4% (2) 0 6.7% (6) 2 9.3% (4) 0 10.8% (19) 2 1.000 1.000 0.746
Nasal polyps, Ever 24% (6) 2 20.9% (18) 6 37.5% (15) 3 19% (31) 15 0.743 0.258 0.591
Nasal (polyps / sinus) surgery, Ever 32% (8) 2 31.3% (26) 13 35.7% (15) 1 19.3% (31) 17 0.949 0.757 0.145
Urticaria or Angioedema, Ever 7.4% (2) 0 13.3% (12) 2 7.0% (3) 0 6.8% (12) 2 0.517 1.000 1.000
OSA, Ever 11.1% (3) 0 4.4% (4) 2 4.7% (2) 0 11.5% (20) 4 0.350 0.367 1.000
Eczema, Ever 25.9% (7) 0 33.0% (30) 1 25.6% (11) 0 21.6% (38) 2 0.489 1.000 0.614